Three of China's coronavirus vaccines are under trials in Asia and South America.
The COVID-19 vaccine Phase III trials conducted by Chinese companies in countries outside China will help Chinese vaccines capture market share in Asian and South and Central American countries, according to a report from GlobalData.
Pharma companies across the globe have been working to develop a vaccine against the virus. GlobalData found that globally, 60 COVID-19 vaccines are under development, with four out of 13 Phase III vaccines are from Chinese companies.
Further, three out of the four Chinese vaccines are undergoing clinical trials in South and Central American countries including Argentina, Brazil, and Chile, whilst two vaccines are being evaluated in Bangladesh, Indonesia, and Pakistan.
The report noted that Brazil and Argentina stood in third and sixth positions in the list of top 10 countries with confirmed cases of COVID-19.
“It seems Chinese companies will focus on launches in Asian and South and Central American countries initially using country-specific clinical trial data as the likelihood of Chinese vaccines to be accepted in those markets is high,” GlobalData's pharma analyst Venkat Kartheek Vale commented.
Further, Chinese players have been struggling to establish themselves in Europe and North American countries against major players such as AstraZeneca, Moderna and Pfizer, the report added.
“Moreover, with lack of late-stage clinical trials from key players like Moderna and Pfizer in Asian countries and AstraZeneca focusing only in India with a Phase II/III study through its partner, Serum Institute of India provides Chinese companies with greater advantage to focus on Asian markets,” Vale added.
Do you know more about this story? Contact us anonymously through this link.